ZLAB · Zai Lab Ltd
$21.53
+3.16 (+17.17%)
At close · Aug 6
Earnings today
View the 10-Q filed May 7, 2026
Customer concentration
— top customer 25% of receivables
One customer — 25% of receivables (As of March 31, 2026)
“As of March 31, 2026, our largest customer accounted for approximately 25% of our total accounts receivable collectively.”
Market Cap
$26.89B
Shares
1.46B
Zai Lab Ltd Earnings Call Transcripts
Every quarterly earnings call for Zai Lab Ltd (ZLAB) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲33.5%
$57.54M
−$161.19M
'22 Q3
22-11-09
▲42.4%
$62.60M
−$61.78M
'22 Q4
23-03-01
▲34.4%
$62.80M
−$49.14M
'23 Q1
23-05-09
▲42.9%
$68.86M
−$120.89M
'23 Q2
23-08-07
▲20.3%
$69.23M
−$69.15M
'23 Q3
23-11-07
▲5.2%
$65.83M
−$95.41M
'23 Q4
24-02-27
▲38.8%
$87.15M
−$53.47M
'24 Q1
24-05-08
▲45.9%
$100.50M
−$80.28M
'24 Q2
24-08-06
▲47.7%
$102.27M
−$41.67M
'24 Q3
24-11-12
▲65.7%
$109.07M
−$81.68M
'24 Q4
25-02-27
▲22.2%
$106.49M
−$48.44M
'25 Q1
25-05-08
▲9.4%
$109.98M
−$40.73M
'25 Q2
25-08-07
▲13.5%
$116.09M
−$35.96M
'25 Q3
25-11-06
▲17%
$127.60M
−$50.37M
'25 Q4
26-02-26
LATEST
▼6.5%
$99.61M
−$51.02M
'26 Q1
26-05-07
Earnings call
FY26 · Q2
2026-08-06
Zai Lab Ltd Q2 FY2026 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-05-07
Zai Lab Ltd Q1 FY2026 Earnings Call
Confident tone
Global collaborations with Amgen and Boehringer Ingelheim
ZL1503 IL-13/IL-31 bi-specific in atopic dermatitis
Pipeline R&D engine and AI/data-driven approaches
Revenue
$99.61M
▼ 6.5% YoY Diluted EPS
$-0.05
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-26
Zai Lab Ltd Q4 FY2025 Earnings Call
Confident tone
Global pipeline / zoci DLL3 ADC
Execution risk and Phase III design uncertainties
KarXT (xanomeline-trospium) launch in China
Revenue
$127.60M*
▲ 17% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-06
Zai Lab Ltd Q3 FY2025 Earnings Call
Confident tone
ZL1503 immunology / atopic dermatitis
Pivotal/registrational milestones and BLA submission
Regional immunology and partner updates (VivGuard, Vertex)
Revenue
$116.09M
▲ 13.5% YoY Diluted EPS
$-0.03
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
Zai Lab Ltd Q2 FY2025 Earnings Call
Confident tone
VYVGART commercial momentum and label expansion
Global pipeline and DLL3 ADC (ZL-1310)
Near-term regulatory milestones and launches
Revenue
$109.98M
▲ 9.4% YoY Diluted EPS
$-0.04
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
Zai Lab Ltd Q1 FY2025 Earnings Call
Confident tone
VYVGART franchise growth
FDA regulatory environment uncertainty
Global pipeline / ZL-1310 DLL3 ADC
Revenue
$106.49M
▲ 22.2% YoY Diluted EPS
$-0.04
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-27
Zai Lab Ltd Q4 FY2024 Earnings Call
Confident tone
VYVGART Launch and Expansion
ZL-1310 DLL3 ADC in Small Cell Lung Cancer
Global Pipeline and R&D Progress
Revenue
$109.07M*
▲ 65.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-12
Zai Lab Ltd Q3 FY2024 Earnings Call
Confident tone
VYVGART commercial launch and growth
Global pipeline expansion and internal R&D
Late-stage regulatory approvals and upcoming launches
Revenue
$102.27M
▲ 47.7% YoY Diluted EPS
$-0.04
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-06
Zai Lab Ltd Q2 FY2024 Earnings Call
Confident tone
VYVGART commercial launch
R&D pipeline progress
ZEJULA and other commercial products
Revenue
$100.50M
▲ 45.9% YoY Diluted EPS
$-0.08
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-08
Zai Lab Ltd Q1 FY2024 Earnings Call
Revenue
$87.15M
▲ 38.8% YoY Diluted EPS
$-0.05
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-27
Zai Lab Ltd Q4 FY2023 Earnings Call
Confident tone
VYVGART launch and NRDL inclusion
Revenue growth and 2024 outlook
Neuroscience pipeline and label expansion
Revenue
$65.83M*
▲ 5.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-07
Zai Lab Ltd Q3 FY2023 Earnings Call
Revenue
$69.23M
▲ 20.3% YoY Diluted EPS
$-0.07
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-07
Zai Lab Ltd Q2 FY2023 Earnings Call
Revenue
$68.86M
▲ 42.9% YoY Diluted EPS
$-0.13
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-09
Zai Lab Ltd Q1 FY2023 Earnings Call
Revenue
$62.80M
▲ 34.4% YoY Diluted EPS
$-0.05
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-01
Zai Lab Ltd Q4 FY2022 Earnings Call
Revenue
$62.60M*
▲ 42.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-09
Zai Lab Ltd Q3 FY2022 Earnings Call
Revenue
$57.54M
▲ 33.5% YoY Diluted EPS
$-0.17
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-09
Zai Lab Ltd Q2 FY2022 Earnings Call
Revenue
$48.18M
▲ 30.4% YoY Diluted EPS
$-0.14
Rev · 7q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-10
Zai Lab Ltd Q1 FY2022 Earnings Call
Revenue
$46.72M
▲ 132.4% YoY
Rev · 6q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-03-01
Zai Lab Ltd Q4 FY2021 Earnings Call
Revenue
$43.96M
▲ 191.3% YoY
Rev · 5q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-09
Zai Lab Ltd Q3 FY2021 Earnings Call
Revenue
$43.10M
Rev · 4q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-09
Zai Lab Ltd Q2 FY2021 Earnings Call
Revenue
$36.94M
Rev · 3q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-10
Zai Lab Ltd Q1 FY2021 Earnings Call
Revenue
$20.10M
Rev · 2q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-03-01
Zai Lab Ltd Q4 FY2020 Earnings Call
Revenue
$15.09M
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q2
2020-06-30
Zai Lab Ltd Q2 FY2020 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Showing 1–24 of 24 earnings calls
Key facts
CIK
1704292
CUSIP
98887Q104
13F (30d)
31 filings
19 filers
Visit website
Investor relations